Sareum Holdings PLC Japan and Singapore Patent Grants

TIDMSAR

Sareum Holdings PLC

17 October 2016

 
 (AIM: SAR)   17 October 2016 
 

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Japan and Singapore Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors

Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with Sareum's Aurora+FLT3 kinase inhibitor programme.

These patents(*) describe compounds that inhibit the activity of Aurora and FLT3 kinase enzymes and the medical use of these compounds, particularly in the treatment of cancer. The granting of this patent in Japan means that Sareum will now have approved patent protection in all major territories for its Aurora+FLT3 kinase inhibitor programme. The Company announced that similar patents were to be granted in the USA and Europe in September 2015 and in China in August 2016.

Sareum's Aurora+FLT3 kinase inhibitor programme targets acute myeloid leukaemia (AML) and other leukaemias and lymphomas. In disease models of AML, the preclinical development candidate molecule demonstrates greater than 98% tumour inhibition. Preclinical development studies to obtain approval for human clinical trials are being undertaken in collaboration with, and funded by, Hebei Medical University Biomedical Engineering Center (HMUBEC) in China.

* Japanese Patent Application no. 2014-555250, Singapore Patent Application no. 11201404277W

Sareum's CSO, Dr John Reader, commented: "These notifications of patent grants in Japan and Singapore complete the protection of the intellectual property associated with Sareum's Aurora+FLT3 programme in all the major territories, enhancing our negotiating position with potential licence partners".

For further information:

 
Sareum Holdings plc 
Tim Mitchell                                      01223 497 700 
WH Ireland Limited (Nominated Adviser and 
 Co-Broker) 
Chris Fielding / Nick Prowting                    020 7220 1666 
Hybridan LLP (Co-Broker) 
Claire Noyce / William Lynne                      020 3764 2341/2342 
The Communications Portfolio 
 (Sareum Media enquiries) 
Ariane Comstive 
 [e-mail]   07785 922 354 
 

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed ProNAi Therapeutics in September 2016.

SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL(R) can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAAKQDKABDDAKD

(END) Dow Jones Newswires

October 17, 2016 02:00 ET (06:00 GMT)